Skip to main content

Nuvera's 'The PURE Report' Announces the Best-in-Class Pharmaceutical Support Programs for 2021 in Neurology and Oncology

CEDAR KNOLLS, N.J. - June 16, 2021 - (Newswire.com)

Nuvera Life Science Consulting, an expert advisor on patient-centric experiences for specialty therapeutics, has announced the best-in-class pharma patient support programs in Neurology and Oncology for 2021. This is the third installment of Nuvera's groundbreaking PURE Report series — the industry's first independent, standardized assessment of healthcare provider (HCP) satisfaction with patient support programs.

The PURE Report uses a unique blend of variables to holistically evaluate support programs based on HCP responses. This proprietary algorithm determines the best-in-class programs based on aided and unaided inputs from about 500 MDs and support staff from each therapeutic area.

The PURE Report: 2021 Neurology awarded Biogen as having the best-in-class program in Neurology, which was announced at Informa's Patient Support Services Congress on June 15, 2021. Biogen's success with the physicians gave them a distinct edge against competitors, though they did perform well among support staff as well.

For the PURE Report: 2021 Oncology, Pfizer was singled out as having the best-in-class program in Oncology. Pfizer's success comes as a result of recent popularity amongst practices' support staff, giving them the win in the highly competitive oncology marketplace.

The PURE Report's comprehensive analysis consists of two separate parts: a syndicated research report that interprets data on HCP perceptions of various program interactions, their service expectations, and their preferred manufacturer programs; and a company-specific report, which analyzes manufacturer rankings across the seven PURE indices, with a spotlight on individual companies.

"This is the third year we are running this research; we've collected almost 3,000 responses to date, which is a wealth of benchmarking data," said Nuvera's Jens Kulstad, who spearheaded the research. "The PURE Report: Neurology 2021 and Oncology 2021 allows us to comprehensively compare company performance and award a best-in-class company. We can also compare results against previous years and see how they are changing over time."

The PURE Report: Neurology 2021 and Oncology 2021 is soon available for industry. Nuvera will present highlights from the research at upcoming conferences. For additional information, please see www.thepurereport.com or contact@thepurereport.com.

About Nuvera Life Science Consulting

Nuvera Life Science Consulting helps the world's leading pharmaceutical and biotech companies deliver impactful patient and HCP support experiences for specialty and rare-disease therapies. Nuvera excels at uncovering patient/HCP needs and crafting and helping execute seamless treatment experiences that enhance patients' ability to obtain, start, and stay on therapies. To learn more, please visit nuveracg.com.

Contact:
The PURE Report

Jens Kulstad
Manager, PURE Report
jens.kulstad@nuveracg.com
www.thepurereport.com




Press Release Service by Newswire.com

Original Source: Nuvera's 'The PURE Report' Announces the Best-in-Class Pharmaceutical Support Programs for 2021 in Neurology and Oncology

Recent Quotes

View More
Symbol Price Change (%)
AMZN  198.79
-0.81 (-0.41%)
AAPL  255.78
-5.95 (-2.27%)
AMD  207.32
+1.38 (0.67%)
BAC  52.55
+0.03 (0.06%)
GOOG  306.02
-3.35 (-1.08%)
META  639.77
-10.04 (-1.55%)
MSFT  401.32
-0.52 (-0.13%)
NVDA  182.81
-4.13 (-2.21%)
ORCL  160.14
+3.66 (2.34%)
TSLA  417.44
+0.37 (0.09%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.